Previous 10 |
Key Highlights: Immuron achieved 66% YoY growth in worldwide sales for the third quarter of FY19, ending March 31, 2019. In Australia Q3 sales of Travelan® surged ahead, growing 73% YoY. In the US Q3 sales of Travelan® were similarly strong, growing 60% YoY. During Q3 F...
Gainers: Reebonz Holding (NASDAQ: RBZ ) +111% . Castor Maritime (NASDAQ: CTRM ) +43% . Anadarko Petroleum (NYSE: APC ) +33% . Immuron (NASDAQ: IMRN ) +27% . Enlivex Therapeutics (NASDAQ: ENLV ) +17% . Kitov Pharma (NASDAQ: KTOV ) +17% . Renren (NYSE: RENN ) +15% . Summit Wirel...
Most developers of therapies to treat nonalcoholic steatohepatitis (NASH) are under modest pressure as investors remain unimpressed with the initial announcements from The International Liver Congress in Vienna. More news on: Intercept Pharmaceuticals, Inc., Gilead Sciences, Inc., Enanta P...
Gainers: China Bat Group (NASDAQ: GLG ) +66% . Papa Murphy's Holdings (NASDAQ: FRSH ) +31% . Phunware (NASDAQ: PHUN ) +22% . Evofem Biosciences (NASDAQ: EVFM ) +18% . American Renal Associates Holdings (NYSE: ARA ) +15% . Acer Therapeutics (NASDAQ: ACER ) +14% . ZK Internation...
C. difficile remains a major medical problem, causing an estimated annual economic burden of more than USD $10 billion globally, with 28,000 deaths per year in the U.S. alone U.S. Patent Office issues patent covering Immuron’s drug composition for treatment of C. dif...
Key Points Immuron to develop U.S. registration dossier for IMM-124E for Travelers’ Diarrhea Company anticipates significant inflection in sales with successful FDA registration of IMM-124E Company to pursue rapid path for clinical development of IMM-124E Travelan ...
Clinical Trials NASH is a progressive chronic liver disease with many causal pathogenic factors. We have learnt from research that dysregulation of the glucose and lipid metabolic pathways could be associated with the development of NASH. Inflammation and activation of the apoptotic (i.e. ce...
Key Highlights: Immuron achieved 7% YoY growth in worldwide sales for the first half of FY19. In the US, Travelan® exhibited double-digit growth for this period, with sales 10% higher than observed for the same time period in the last financial year. In Australia, FY19 1H sal...
CNBC reports that nonalcoholic steatohepatitis or NASH is "next big thing" for drug makers, a potential market of $35B or more if pharma/biotech firms can successfully navigate the regulatory process, a task none has accomplished to date. More news on: Intercept Pharmaceuticals, Madrigal...
News, Short Squeeze, Breakout and More Instantly...
Immuron Limited Company Name:
IMRN Stock Symbol:
NASDAQ Market:
Immuron Limited (IMRN) is expected to report for Q4 2023
MELBOURNE, Australia, May 03, 2024 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian based and globally integrated bio...
MELBOURNE, Australia, May 03, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, advises that Stephen Anastasiou has resigned from his position as Non-Executive Director effective today to focus on his other bu...